Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,126 public posts
Filter results
Docetaxel rechallenge in mPCa.
expand PMID: 32985144 DOI: 10.4111/icu.20200214 Free article Abstract Purpose: To assess the efficacy and safety of docetaxel rechallenge in the salvage setting in metastatic
castration
-resistant prostate cancer (mCRPC) patients.
expand PMID: 32985144 DOI: 10.4111/icu.20200214 Free article Abstract Purpose: To assess the efficacy and safety of docetaxel rechallenge in the salvage setting in metastatic
castration
-resistant prostate cancer (mCRPC) patients.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Is VERU-111 (Novel Oral Tubulin Inhibitor) similar to Fenbendazole or Mebendazole?
111 inactivates by cleaving poly ADP ribose polymerase (PARP), which is important for DNA repair in cancer cells. https://www.urotoday.com/conference-highlights/esmo-2020/prostate-cancer/124493-esmo-virtual-congress-2020-phase-1b-2-study-of-veru-111-novel-oral-tubulin-inhibitor-in-men-with-metastatic-
castration
-resistant-prostate-cancer-who-failed-an-androgen-blocking-agent.html
111 inactivates by cleaving poly ADP ribose polymerase (PARP), which is important for DNA repair in cancer cells. https://www.urotoday.com/conference-highlights/esmo-2020/prostate-cancer/124493-esmo-virtual-congress-2020-phase-1b-2-study-of-veru-111-novel-oral-tubulin-inhibitor-in-men-with-metastatic-
castration
-resistant-prostate-cancer-who-failed-an-androgen-blocking-agent.html
cigafred
in
Advanced Prostate Cancer
4 years ago
Nonmetastatic, Castration-Resistant ProstateCancer and Survival with Darolutamide
Darolutamide offers OS advantage without serious negative side effects. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001342?articleTools=true
Darolutamide offers OS advantage without serious negative side effects. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001342?articleTools=true
tango65
in
Advanced Prostate Cancer
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
BAT, dutasteride, and my search for truth, Part 2 of 2
immunohistochemical findings in human PCa tissue samples, suggesting that ERß EXPRESSION IS LOST IN HIGH-GRADE TUMORS (42,43,44)” BUT “Recently, a theory of switching roles of ER during prostate carcinogenesis has been proposed, based on observations that elevated ERß protein levels are detected in
castration
-resistant
immunohistochemical findings in human PCa tissue samples, suggesting that ERß EXPRESSION IS LOST IN HIGH-GRADE TUMORS (42,43,44)” BUT “Recently, a theory of switching roles of ER during prostate carcinogenesis has been proposed, based on observations that elevated ERß protein levels are detected in
castration
-resistant
cigafred
in
Advanced Prostate Cancer
4 years ago
Wondering what to expect
I am feeling hopeful, but understand it's just a matter of time before I become
castration
resistant. I don't want to live forever, but another 5 years would be nice.
I am feeling hopeful, but understand it's just a matter of time before I become
castration
resistant. I don't want to live forever, but another 5 years would be nice.
CountryJoe
in
Advanced Prostate Cancer
4 years ago
Phase 1b/2 Study of VERU-111, Novel, Oral Tubulin Inhibitor, in mCRPC Who Failed an Androgen Blocking Agent
https://www.urotoday.com/conference-highlights/esmo-2020/prostate-cancer/124493-esmo-virtual-congress-2020-phase-1b-2-study-of-veru-111-novel-oral-tubulin-inhibitor-in-men-with-metastatic-
castration
-resistant-prostate-cancer-who-failed-an-androgen-blocking-agent.html?
https://www.urotoday.com/conference-highlights/esmo-2020/prostate-cancer/124493-esmo-virtual-congress-2020-phase-1b-2-study-of-veru-111-novel-oral-tubulin-inhibitor-in-men-with-metastatic-
castration
-resistant-prostate-cancer-who-failed-an-androgen-blocking-agent.html?
tango65
in
Advanced Prostate Cancer
4 years ago
Apalutamide and Overall Survival in Prostate Cancer
BACKGROUND The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic
castration
-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo.
BACKGROUND The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic
castration
-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Update on ARV-110 for anyone looking for a trial with a new drug approach - first in class - fast tracked May 2019
"Arvinas is currently evaluating ARV-110 in a Phase 1 study for men with
castration
-resistant metastatic prostate cancer (mCRPC) who have progressed on standards of care." arvinas.com/pipeline-progra...
"Arvinas is currently evaluating ARV-110 in a Phase 1 study for men with
castration
-resistant metastatic prostate cancer (mCRPC) who have progressed on standards of care." arvinas.com/pipeline-progra...
George71
in
Advanced Prostate Cancer
4 years ago
[EAU-2020] Enzyme inhibition for overcoming CRPC.
-Patrick [1] https://www.urologytimes.com/view/enzyme-inhibition-shows-promise-for-overcoming-
castration
-resistance-in-prostate-cancer
Enzyme inhibition shows promise for overcoming
resistance in prostate cancer July 20, 2020 Cheryl Guttman Krader, BS, Pharm Inhibition of steroid sulfatase
-Patrick [1] https://www.urologytimes.com/view/enzyme-inhibition-shows-promise-for-overcoming-
castration
-resistance-in-prostate-cancer
Enzyme inhibition shows promise for overcoming
resistance in prostate cancer July 20, 2020 Cheryl Guttman Krader, BS, Pharm Inhibition of steroid sulfatase
pjoshea13
in
Advanced Prostate Cancer
4 years ago
BRCA 2 and Platinum Based Chemotherapy
– Emily Miller, MD IMPORTANCE DNA repair gene aberrations occur in 20% to 30% of patients with
castration
-resistant prostate cancer (CRPC), and some of these aberrations have been associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition platinum-based treatments.
– Emily Miller, MD IMPORTANCE DNA repair gene aberrations occur in 20% to 30% of patients with
castration
-resistant prostate cancer (CRPC), and some of these aberrations have been associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition platinum-based treatments.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Lynparza & BRCA1, BRCA2 or ATM-mutated cancer Survival.
"The new data also give the AZ-Merck team a leg up on rival drugmaker Clovis Oncology, which nabbed an OK for its PARP inhibitor, Rubraca, in BRCA-mutated metastatic,
castration
-resistant prostate cancer just days before Lynparza did.
"The new data also give the AZ-Merck team a leg up on rival drugmaker Clovis Oncology, which nabbed an OK for its PARP inhibitor, Rubraca, in BRCA-mutated metastatic,
castration
-resistant prostate cancer just days before Lynparza did.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Synergy between radiation of metastases and immunotherapy confirmed
Castration
-resistant patients (who'd already had docetaxel) survived longer with the combination than with ipi alone (ipi has no effect on its own). In a short-term phase 2 trial, Xofigo (radium 223 chloride) was combined with Provenge (sipuleucel-T) in
castration
-resistant patients.
Castration
-resistant patients (who'd already had docetaxel) survived longer with the combination than with ipi alone (ipi has no effect on its own). In a short-term phase 2 trial, Xofigo (radium 223 chloride) was combined with Provenge (sipuleucel-T) in
castration
-resistant patients.
Tall_Allen
in
Advanced Prostate Cancer
4 years ago
Yervoy An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resist
recent analysis shows that long-term survival after 3, 4 and 5 years is two -- three times higher in the immunotherapy arm as opposed to the placebo arm. An antibody that targets CTLA-4, a so-called checkpoint inhibitor (CPI), can block this deactivation, thereby reactivating the immune system once
recent analysis shows that long-term survival after 3, 4 and 5 years is two -- three times higher in the immunotherapy arm as opposed to the placebo arm. An antibody that targets CTLA-4, a so-called checkpoint inhibitor (CPI), can block this deactivation, thereby reactivating the immune system once
George71
in
Advanced Prostate Cancer
4 years ago
Entering Clinical Trials
My recent biopsy shows no evidence of a new BRAC1/2 mutation so the PARB inhibitors are not an option for me as a new
castration
resistant metastatic prostate cancer patient. Made the decision to remain in Phoenix to enter a clinical trial with the Mayo Clinic this month.
My recent biopsy shows no evidence of a new BRAC1/2 mutation so the PARB inhibitors are not an option for me as a new
castration
resistant metastatic prostate cancer patient. Made the decision to remain in Phoenix to enter a clinical trial with the Mayo Clinic this month.
Cleodman
in
Advanced Prostate Cancer
4 years ago
Treatment Considerations for Prostate Cancer Progressing After Combination Therapy for mCSPC
utm_source=newsletter_8140&utm_medium=email&utm_campaign=treatment-considerations-for-prostate-cancer-from-localized-disease-through-
castration
-sensitive-metastatic-disease-asco-2020-educational-symposium-plenary-session-highlights
utm_source=newsletter_8140&utm_medium=email&utm_campaign=treatment-considerations-for-prostate-cancer-from-localized-disease-through-
castration
-sensitive-metastatic-disease-asco-2020-educational-symposium-plenary-session-highlights
tango65
in
Advanced Prostate Cancer
4 years ago
Metformin may delay PCa progression.
More from ESMO 2020: https://www.mdedge.com/hematology-oncology/article/228803/genitourinary-cancer/metformin-may-delay-prostate-cancer "Adding metformin to standard care for advanced prostate cancer appeared to lengthen time to
castration
-resistant disease in a small, randomized trial.
More from ESMO 2020: https://www.mdedge.com/hematology-oncology/article/228803/genitourinary-cancer/metformin-may-delay-prostate-cancer "Adding metformin to standard care for advanced prostate cancer appeared to lengthen time to
castration
-resistant disease in a small, randomized trial.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Darolutamide improves OS 31% at three years with good SE profile.
query=TOC September 10, 2020 N Engl J Med 2020; 383:1040-1049 DOI: 10.1056/NEJMoa2001342 Abstract BACKGROUND Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic,
castration
-resistant prostate cancer.
query=TOC September 10, 2020 N Engl J Med 2020; 383:1040-1049 DOI: 10.1056/NEJMoa2001342 Abstract BACKGROUND Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic,
castration
-resistant prostate cancer.
MateoBeach
in
Advanced Prostate Cancer
4 years ago
Metformin: Preliminary Results of Trial in Advanced Prostate Cancer (MANSMED)
In the assessment of the primary outcome, patients receiving metformin had a longer time to
castration
-resistant disease (median 29 months, 95% confidence interval 25 to 33) than those randomized to placebo (20 months, 95% confidence interval 16 to 24, p=0.01).
In the assessment of the primary outcome, patients receiving metformin had a longer time to
castration
-resistant disease (median 29 months, 95% confidence interval 25 to 33) than those randomized to placebo (20 months, 95% confidence interval 16 to 24, p=0.01).
noahware
in
Advanced Prostate Cancer
4 years ago
Second opinions
I am looking for suggestions for getting another opinion from the most advanced minds/centers for handling
castration
resistant metastatic prostate cancer. Something along the lines of MD Anderson? Thanks
I am looking for suggestions for getting another opinion from the most advanced minds/centers for handling
castration
resistant metastatic prostate cancer. Something along the lines of MD Anderson? Thanks
Dino24
in
Advanced Prostate Cancer
4 years ago
Rucaparib in Metastatic Castration-Resistant Prostate Cancer With BRCA1/2 Alteration
BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration
-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors.
BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration
-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors.
Balsam01
in
Advanced Prostate Cancer
4 years ago
1
...
27
28
29
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1003 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest